Johns Hopkins Medicine Launches TULSA-PRO® System for Prostate Cancer Treatment
TORONTO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) has announced that The Johns Hopkins Hospital is the first institution to treat a non-clinical-trial prostate cancer patient using the Company’s cutting-edge TULSA-PRO® system. This significant milestone marks the official launch of TULSA-PRO and aligns with the inauguration of Johns Hopkins Medicine's state-of-the-art interventional MRI (iMRI) suite, highlighting the evolution of MRI from mere diagnostic imaging to an advanced therapeutic platform.
Breakthrough in Prostate Care: The TULSA Procedure™
The TULSA Procedure™ represents a pivotal advancement in the treatment of prostate cancer and benign prostatic hyperplasia (BPH). Utilized by healthcare professionals, this innovative procedure involves robotically controlled directional ultrasound, which is delivered from within the urethra to precisely heat prostate tissue to ‘kill temperature’ of 55-57°C. This technique minimizes damage to surrounding nerves while ensuring real-time MRI thermography offers continuous visualization, allowing for autonomous temperature adjustments throughout.
Key benefits of the TULSA-PRO® system include:
- No procedural blood loss
- No overnight hospital stays required
- Faster recovery times
- Reduced side effects traditionally linked with surgical and radiation treatments, such as urinary incontinence and erectile dysfunction
Insights from Leadership
Arun Menawat, CEO and Chairman of Profound Medical, commented on the launch, stating, “The implementation of TULSA-PRO in a newly built interventional MR suite designed for surgical procedures represents a significant shift towards precision medicine. It is fitting that an esteemed institution like Johns Hopkins Medicine is leading this innovation.” He noted that Johns Hopkins played a vital role in the clinical development of TULSA-PRO through its participation in pivotal clinical trials, including TACT and the subsequent CAPTAIN trial.
About Profound Medical Corp.
Profound Medical Corp. is a commercial-stage medical device company specializing in AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The TULSA-PRO® technology merges real-time MRI with AI-enhanced planning and robotically driven transurethral ultrasound to create a highly effective treatment option across the prostate disease spectrum. This includes low-, intermediate-, or high-risk prostate cancer, as well as hybrid patients with both prostate cancer and BPH.
Profound is also working on another innovative platform, Sonalleve®, which is CE marked and approved for various treatments, including uterine fibroids and pain related to bone metastases. The Company is exploring further applications for Sonalleve in non-invasive cancer treatments.
Forward-Looking Statements
This release includes forward-looking statements regarding Profound and its operations, which may involve uncertainties regarding future financial performances and the anticipated efficacy of the Company's technologies. Factors influencing these outcomes include regulatory approvals and dynamics within the medical device industry.
For further information, please contact:
- Stephen Kilmer, Investor Relations: skilmer@profoundmedical.com, T: 647.872.4849
- Susan Thomas, Public Relations: sthomas@profoundmedical.com, T: 619.540.9195